Transforming Healthcare for Everyone.
Evelo’s small intestinal axis, SINTAX™, platform has the potential to transform the global treatment of all stages of inflammatory disease.
Positive Phase 2 clinical data with our lead candidate EDP1815 in psoriasis confirm that Evelo can harness SINTAX to treat systemic inflammatory diseases with an orally delivered medicine observed to have placebo-like safety and tolerability. EDP1815 – with its convenient oral delivery, together with affordable pricing – opens up the opportunity to treat hundreds of millions of people who are limited by today’s medicines.
This is only the beginning.
Effective, Safe, Well Tolerated, Convenient and Affordable
Our product candidates are non-live single strains of microbes and extracellular vesicles that are room-temperature stable and can be taken orally. In a Phase 2 clinical trial, our lead product candidate was well tolerated and safety data was comparable to placebo.
SINTAX™: A NEWLY UNCOVERED AREA OF HUMAN BIOLOGY
Treatments for multiple diseases
SINTAX medicines have the potential to treat a range of inflammatory conditions, including psoriasis and atopic dermatitis, arthritic diseases, inflammatory bowel disorders, neuroinflammatory diseases, such as Parkinson’s, Alzheimer’s and dementia, and cardiovascular conditions and metabolic disease, such as obesity and diabetes.
Advancing our medicines to patients who need them
We are rapidly progressing our product candidates through research and clinical development in order to realize our vision of providing effective, safe, convenient, and affordable medicines to patients who need them.
Life as an Evelonian
We have an ambitious, passionate, and dedicated team who are driven to have a major impact on global healthcare.
As a company, we are committed to providing a phenomenal growth environment and opportunities for employees to realize their potential.
Stay in the Know
May 12, 2022
Evelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights
April 21, 2022
Evelo Biosciences Appoints John Maraganore, Ph.D. and Tassos Gianakakos as Strategic Advisors
April 14, 2022
Evelo Biosciences Provides Updated Guidance on Advancing Clinical Inflammation Programs
March 24, 2022
Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
March 11, 2022
The Future: A no regrets treatment for all stages of psoriasis and broader inflammatory disease - PIONEERING A NEW SAFE AND WELL TOLERATED ORAL THERAPY THAT TARGETS THE SMALL INTESTINAL AXIS
March 9, 2022